Skip to content
Screener

Haemonetics HAE Payments for purchase of capped call related to convertible notes

Payments for purchase of capped call related to convertible notes at other companies

Compass logo
CompassCOMP
$97M
Compass logo
CompassCOMP
$97M
Voyager Technologies logo
Voyager TechnologiesVOYG
$16.69M
Fluence Energy, Inc. logo
Fluence Energy, Inc.FLNC
$0-100%
Fluence Energy, Inc. logo
Fluence Energy, Inc.FLNC
$0-100%
Mirion Technologies logo
Mirion TechnologiesMIR
$20.65M

Other financials

Income statement

See full
Revenue$339.4M+5.6%
Gross profit$202.8M+5.5%
Operating income$57.5M+6.7%
Net income$33.0M-3.0%
EPS (diluted)$0.72+2.9%

Balance sheet

See full
Cash & equivalents$223.4M-23.7%
Total debt$1.2B-4.1%
Total equity$837.1M-5.1%
Total assets$2.4B-3.9%

Cash flow

See full
Operating cash flow$52.3M+201%
CapEx$7.9M+111%
Free cash flow$44.4M+226%

Valuation

See full
Market cap$4B+58.1%
Enterprise value$4.95B+43.0%
P/E26.6×-10.9×
P/S+1.1×

Profitability

See full
Gross margin59%+2.1pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin21.5%+7.5pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.4×0.0×
Current ratio3.1×+1.4×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept hae:PaymentsForPurchaseOfCappedCallRelatedToConvertibleNotes.

The source filing: Haemonetics’s 10-K, filed May 20, 2026.

Filed
May 20, 2026, 6:31 AM EDT
Fiscal year
FY2026
Accession
0000313143-26-000050
Line itemYear Ended / March 28,2026Year Ended / March 29,2025Year Ended / March 30,2024
Cash Flows from Financing Activities:
Proceeds from issuance of convertible notes700,000
Repayment and repurchase of convertible notes(300,000)(185,500)
Purchase of capped call related to convertible notes(88,200)
Term loan borrowings250,000
Term loan redemption(262,500)
Repayment of term loan borrowings(6,250)(4,688)(12,250)
Proceeds from revolving facility300,000110,000

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

FAQ

What is Haemonetics's payments for purchase of capped call related to convertible notes?
Haemonetics (HAE) reported payments for purchase of capped call related to convertible notes of $0 in Q1 2026.
How has Haemonetics's payments for purchase of capped call related to convertible notes changed year-over-year?
Haemonetics's payments for purchase of capped call related to convertible notes decreased by 100.0% year-over-year, from $22.05M to $0.
What does payments for purchase of capped call related to convertible notes mean?
This represents the cash outflow for purchasing derivative instruments designed to mitigate the potential dilution from convertible debt securities. These instruments effectively raise the conversion price of the debt, protecting existing shareholders from excessive equity dilution. It reflects the company's strategy for managing capital structure and equity-linked financing costs.

Ask your AI about Haemonetics's payments for purchase of capped call related to convertible notes.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude